# Choline - final

Choline-SAM-GABA Dysregulation as a Unified Metabolic Framework Linking Cancer and Alzheimer's Disease Through Mirror Pathologies



IL WOONG CHOI

Independent Researcher, OXFORD, UK

Email: iwchoikr@gmail.com

ORCID: 0009-0004-1292-0610



Abstract

Cancer and Alzheimer's disease represent two prevalent age-related pathologies exhibiting a striking inverse epidemiological relationship. This paper proposes a unified metabolic framework linking both diseases through dysregulation of the choline-GABA-alpha-ketoglutarate axis. We hypothesize that individuals with deficient GABAergic regulation systems (both ionotropic GABA-A and metabotropic GABA-B) accumulate alpha-ketoglutarate ("cold stress") and experience circadian-dependent charge dysregulation ("darkness stress"), creating permissive conditions for either oncogenic transformation or neurodegenerative autoimmunity. Cancer emerges when epinephrine-mediated proliferative signaling proceeds without proper inhibitory control, manifesting as outward-directed pathology through uncontrolled cellular proliferation. Alzheimer's disease emerges when vasopressin-mediated stress responses cannot discharge externally, redirecting pathology inward as autoimmune-like neurodegeneration. Central to both mechanisms is the energetic equivalence between dual-GABA system deficiency and impaired choline synthesis via S-adenosylmethionine (SAM)-dependent pathways. This framework integrates established hallmarks—metabolic reprogramming, circadian disruption, genomic instability, cholinergic deficiency, and alpha-ketoglutarate dehydrogenase complex dysfunction—into a testable model explaining why these diseases rarely co-occur despite shared metabolic vulnerabilities, and predicting unified therapeutic approaches targeting metabolic restoration and chronotherapeutic optimization.



Keywords: Cancer metabolism, Alzheimer's disease, GABA, alpha-ketoglutarate, choline, circadian rhythms, metabolic reprogramming, neurodegeneration, inverse epidemiology



---



Introduction



The Inverse Epidemiological Relationship

Multiple large-scale epidemiological studies have documented a robust inverse relationship between cancer and Alzheimer's disease (AD). Driver et al. reported that cancer survivors demonstrated a 33% decreased risk of developing AD compared to individuals without cancer history, with smoking-related cancers showing even stronger protection (74% risk reduction) 1. Conversely, individuals with prevalent AD exhibited 69% lower risk of cancer hospitalization 2. This inverse association has been replicated across diverse populations and cancer types, with meta-analyses confirming that AD patients show 47% reduced cancer risk (RR: 0.53) while cancer patients demonstrate 39% reduced AD risk (RR: 0.61) 3,4. Autopsy studies further validate this relationship, revealing substantially decreased cancer prevalence in AD brains compared to age-matched controls 5.



The robustness of this inverse relationship across methodologies—prospective cohort studies, autopsy series, and genetic analyses—suggests fundamental metabolic opposition rather than artifactual under-diagnosis or competing mortality. While some cancer reduction in AD patients reflects decreased screening, the magnitude and consistency of the inverse relationship, particularly in autopsy studies immune to diagnostic bias, demands mechanistic explanation 3,4.



Current Disease Models: Parallel Deficiencies

Contemporary cancer research emphasizes metabolic reprogramming as a hallmark of oncogenesis, with altered choline metabolism representing one of the most consistent metabolic abnormalities across cancer types 6. Elevated phosphocholine and total choline-containing compounds characterize the "cholinic phenotype" observable by magnetic resonance spectroscopy, reflecting upregulated Kennedy pathway activity supporting rapid membrane synthesis for proliferating cells 7,8. Additionally, cancer cells demonstrate circadian disruption—shift workers experiencing circadian rhythm disruption show substantially elevated cancer risk, with the International Agency for Research on Cancer classifying such disruption as a probable human carcinogen 10,11.



Alzheimer's disease research centers on the cholinergic hypothesis, established over two decades ago, which posits that acetylcholine-containing neuron dysfunction substantially contributes to cognitive decline 12. AD brains demonstrate profound cholinergic system degeneration, with choline acetyltransferase activity declining markedly in correlation with cognitive impairment severity 13. Additionally, AD exhibits dramatic reductions (50-75%) in alpha-ketoglutarate dehydrogenase complex (KGDHC) activity across multiple brain regions, preceding overt neurodegeneration and appearing in mild cognitive impairment stages 14,15. Like cancer, AD demonstrates severe circadian disruption—sundowning, sleep-wake cycle reversal, and reduced melatonin production—suggesting shared circadian vulnerability 16,17.



The Hypothesis



We propose that cancer and AD represent alternative manifestations of a shared metabolic vulnerability rooted in dual GABAergic regulatory system deficiency—specifically, simultaneous impairment of ionotropic (GABA-A) and metabotropic (GABA-B) receptor function. This dual deficiency creates two metabolic stress states: (1) "cold stress" through alpha-ketoglutarate accumulation resulting from failed metabolic regulation, and (2) "darkness stress" through circadian dysregulation resulting from lost temporal entrainment. These stress states create permissive conditions for pathology that manifests either as uncontrolled proliferation (cancer) or autoimmune-like neurodegeneration (AD) depending on which stress response pathways activate.



Central to this framework is the recognition that choline synthesis via SAM-dependent phosphatidylethanolamine (PE) methylation represents a major SAM consumer sharing energetic characteristics with GABAergic regulatory systems 18. Both involve internal electron redistribution without net redox changes, creating metabolic equivalence: dual-GABA deficiency energetically equals impaired choline synthesis capacity. This explains the cholinergic deficiency in AD and altered choline metabolism in cancer as manifestations of the same underlying metabolic vulnerability.



The framework explains the inverse epidemiological relationship through mutual exclusivity: individuals with dual-GABA deficiency develop one pathology or the other depending on context (genetic modifiers, stress exposure patterns, tissue vulnerabilities), but rarely both simultaneously as each pathway, once activated, consumes available metabolic resources and dominates the phenotype.



Evolution of Hypothesis



The Choline-SAM-Methylation Axis: Energetic Signature and Disease Vulnerability



Choline Synthesis Through SAM-Dependent PE Methylation

De novo choline synthesis proceeds through sequential methylation of phosphatidylethanolamine to phosphatidylcholine via phosphatidylethanolamine N-methyltransferase (PEMT), consuming three SAM molecules per choline synthesized 18. This pathway represents a major consumer of cellular SAM—indeed, PE methylation may constitute the largest single SAM-consuming process in certain tissues 19. Critically, this synthesis involves only methylation reactions without external electron exchange—pure internal electron redistribution through methyl group transfer.



The energetic signature of SAM-dependent choline synthesis—multiple sequential methylations without net redox changes—creates metabolic equivalence with other anaerobic, non-redox regulatory pathways. This equivalence means that impaired SAM availability or flux directly constrains choline synthesis capacity, linking one-carbon metabolism intimately to membrane lipid production, neurotransmitter synthesis, and epigenetic regulation 20.



PEMT activity and choline synthesis capacity show substantial inter-individual variation based on genetic polymorphisms, dietary intake, and metabolic state. Approximately 30% of hepatic phosphatidylcholine synthesis proceeds through PEMT, with the remainder utilizing dietary choline via the Kennedy pathway. This dual-source dependency creates vulnerability when either pathway fails—genetic PEMT deficiency increases dietary choline requirements, while choline deficiency increases PEMT demands and SAM consumption 21,22.



Choline Dysregulation in Cancer: The Cholinic Phenotype

Activated choline metabolism represents a hallmark of carcinogenesis observable across all tested cancer types 6. The "cholinic phenotype" manifests as elevated phosphocholine, glycerophosphocholine, and total choline-containing compounds detectable by magnetic resonance spectroscopy 7. This metabolic reprogramming reflects multiple enzymatic alterations: upregulated choline kinase-α (CHKα) expression and activity, increased choline transporter expression, and elevated phosphatidylcholine-specific phospholipase C and D activities 8,23.



CHKα upregulation represents a consistent early event in oncogenesis. CHKα catalyzes phosphocholine formation from free choline—the first committed step of the Kennedy pathway producing phosphatidylcholine for membrane synthesis. Cancer cells' uncontrolled proliferation demands continuous membrane phospholipid production, creating enormous choline metabolism flux. Elevated CHKα activity in cancer cells leads to increased CHKα-CHKα homodimer formation exhibiting higher catalytic activity than CHKα-CHKβ heterodimers, amplifying phosphocholine accumulation 9.



Beyond membrane synthesis, altered choline metabolism in cancer connects to epigenetic reprogramming through SAM-dependent methylation. Choline oxidation to betaine provides methyl groups for SAM regeneration from S-adenosylhomocysteine (SAH), linking choline availability to genome-wide DNA and histone methylation patterns. Cancer cells demonstrate paradoxical methylation: global DNA hypomethylation alongside regional hypermethylation at tumor suppressor loci 6. This pattern suggests not absolute choline deficiency but rather dysregulated SAM-dependent methylation flux—the cells possess abundant choline for membrane synthesis but fail to properly regulate methylation reactions.



Choline Deficiency in Alzheimer's Disease: Cholinergic System Collapse

The cholinergic hypothesis of AD, formulated over two decades ago, remains foundational to understanding AD pathogenesis and treatment 12. AD brains demonstrate severe cholinergic system degeneration with marked declines in choline acetyltransferase (ChAT) activity—the enzyme synthesizing acetylcholine from choline and acetyl-CoA 13. This cholinergic deficit correlates strongly with cognitive impairment severity and forms the basis for current AD therapeutics (acetylcholinesterase inhibitors).



Cholinergic abnormalities in AD extend beyond simple neuronal loss. Post-mortem and antemortem studies reveal: altered choline transport, reduced acetylcholine release, modified nicotinic and muscarinic receptor expression, impaired neurotrophin support, and potentially disrupted axonal transport 12. These multiple cholinergic system failures suggest fundamental metabolic insufficiency rather than isolated neurotransmitter deficiency.



Epidemiological evidence supports choline's role in AD prevention—dietary choline intake correlates inversely with AD risk 24. However, choline supplementation trials show mixed results, with simple supplementation failing to overcome underlying metabolic dysfunction. This parallels the limited efficacy of acetylcholinesterase inhibitors, which enhance acetylcholine availability but cannot reverse disease progression. The failure of supplementation-based approaches points toward more fundamental metabolic disruption preventing effective choline utilization even when substrate availability increases.



Basal forebrain cholinergic neurons projecting throughout cortex show particular vulnerability in AD, degenerating early in disease progression 12. These neurons' high metabolic demands and continuous choline requirements for acetylcholine synthesis create vulnerability when choline synthesis or availability becomes compromised. The preferential degeneration of precisely those neurons with highest choline demands supports the hypothesis that impaired choline metabolism contributes causally to AD pathogenesis rather than merely reflecting downstream neuronal loss.



GABA Systems: Dual Regulation, Metabolic Integration, and Energetic Equivalence



Ionotropic and Metabotropic GABA Systems: Distinct Functions



Gamma-aminobutyric acid mediates inhibitory neurotransmission through two mechanistically distinct receptor systems. Ionotropic GABA-A receptors function as ligand-gated chloride channels producing fast inhibitory postsynaptic potentials through direct membrane hyperpolarization 25. Metabotropic GABA-B receptors signal through G-protein-coupled mechanisms with slower kinetics but more sustained and diverse effects, modulating calcium channels, potassium channels, and adenylyl cyclase activity 26.



Beyond neurotransmission, GABA participates directly in intermediary metabolism through the "GABA shunt"—an alternative pathway bypassing alpha-ketoglutarate dehydrogenase in the TCA cycle. Glutamate decarboxylase converts glutamate to GABA, which subsequently converts through GABA transaminase to succinate semialdehyde, then through succinate semialdehyde dehydrogenase to succinate, re-entering the TCA cycle downstream of alpha-ketoglutarate dehydrogenase 27. This shunt provides metabolic flexibility, enabling glutamate disposal and alternative TCA cycle fueling when alpha-ketoglutarate dehydrogenase activity becomes limiting 28.



The GABA shunt's significance extends beyond simple pathway redundancy. In organisms ranging from cyanobacteria to mammals, GABA shunt activity significantly impacts TCA cycle metabolite levels—disrupting the shunt elevates alpha-ketoglutarate (2-oxoglutarate) while reducing downstream metabolites (succinate, malate, citrate). This demonstrates GABA's role not merely as neurotransmitter but as metabolic regulator controlling carbon flow through central metabolism 28.


GABA Regulation of Alpha-Ketoglutarate: Preventing "Cold Stress"

Alpha-ketoglutarate occupies a critical metabolic junction, serving simultaneously as: (1) TCA cycle intermediate, (2) nitrogen acceptor in transamination reactions producing glutamate, (3) substrate for alpha-ketoglutarate-dependent dioxygenases regulating hypoxia signaling (HIF hydroxylases) and epigenetic modifications (TET DNA demethylases, JmjC-domain histone demethylases). Its concentration oscillates based on competing demands: oxidation via KGDHC to proceed through the TCA cycle versus utilization in biosynthetic reactions, epigenetic regulation, or the GABA shunt 29.



We propose that functional GABA systems—particularly ionotropic GABA-A receptors coupled to the GABA shunt—regulate alpha-ketoglutarate accumulation, preventing pathological elevation we term "cold stress." The ionotropic GABA system provides rapid metabolic adjustment through the GABA shunt, channeling glutamate-derived carbon into succinate production, thereby reducing alpha-ketoglutarate levels when accumulation threatens. Deficiency in ionotropic GABA function eliminates this regulatory capacity, allowing alpha-ketoglutarate accumulation that disrupts multiple downstream processes 27.



Alpha-ketoglutarate accumulation disrupts metabolism through several mechanisms: (1) altered glutamate/GABA balance as alpha-ketoglutarate transaminates to glutamate, reducing glutamate decarboxylase substrate for GABA synthesis; (2) impaired mitochondrial function as TCA cycle flux stalls; (3) decreased NADH production limiting ATP synthesis; (4) altered substrate availability for alpha-ketoglutarate-dependent dioxygenases, dysregulating hypoxia responses and epigenetic modifications. This multi-system disruption from alpha-ketoglutarate dysregulation explains how ionotropic GABA deficiency creates metabolic vulnerability underlying both cancer and AD.



Metabotropic GABA and Circadian Entrainment: Preventing "Darkness Stress"

Beyond acute metabolic regulation, GABA systems exhibit circadian rhythmicity with both synthesis and receptor sensitivity varying across the 24-hour cycle. Metabotropic GABA-B receptors particularly contribute to circadian metabolic entrainment, coordinating metabolic flux with light-dark cycles through their sustained G-protein-coupled signaling. This circadian GABA modulation enables temporal segregation of anabolic and catabolic processes, synchronizing cellular metabolism with environmental rhythms 26.



Deficiency in metabotropic GABA function disrupts circadian metabolic entrainment, creating what we term "darkness stress"—nocturnal charge dysregulation occurring when normal compensatory mechanisms fail during dark periods. This manifests as altered nocturnal metabolism, disrupted sleep-wake cycles, and particular vulnerability to stress during circadian transitions (dawn/dusk) when metabolic switching normally occurs. The profound circadian disruption observable in both cancer and AD—shift work cancer risk, sundowning in AD, sleep-wake cycle abnormalities in both conditions—reflects this fundamental loss of circadian-entrained GABAergic regulation 16.



Melatonin serves as the primary hormonal mediator of circadian information, with nocturnal melatonin production entraining peripheral clocks and coordinating tissue-specific circadian gene expression. Both cancer and AD demonstrate reduced melatonin production and disrupted melatonin signaling. Melatonin supplementation shows therapeutic promise in both diseases, though optimal timing differs—supporting the concept that shared circadian vulnerability underlies both pathologies but manifests through different temporal patterns requiring chronotherapy optimization 17,33.



Energetic Equivalence: Dual-GABA Deficiency Equals Impaired Choline Synthesis

The critical insight connecting GABA systems to choline metabolism involves energetic equivalence. Both SAM-dependent choline synthesis and certain GABA-related regulatory processes share a key characteristic: internal electron redistribution without net redox changes 18. SAM-dependent PE methylation involves three sequential methyl group transfers—pure methylation reactions without external electron donors or acceptors. Similarly, the metabolic regulation involving coordinated ionotropic and metabotropic GABA function operates through charge redistribution and metabolic flux control without net oxidation-reduction.



This energetic equivalence means that metabolic states characterized by deficient dual-GABA system function energetically equal states of impaired SAM-dependent choline synthesis capacity. The cell cannot simultaneously maintain robust dual-GABA regulatory function and robust SAM-dependent choline synthesis when metabolic resources become constrained. This explains several otherwise puzzling observations: (1) why cholinergic neurons show particular vulnerability in AD—they require both robust choline synthesis for acetylcholine production and functional GABAergic regulation; (2) why cancer cells show altered choline metabolism despite adequate substrate availability—the metabolic reprogramming underlying oncogenesis disrupts the energetic balance; (3) why both diseases show circadian vulnerability—the temporal dynamics of SAM production and GABA function require coordination.



The energetic equivalence predicts that individuals with genetic or acquired deficiencies in dual-GABA function will necessarily exhibit compromised choline synthesis capacity, creating vulnerability to both cancer (through loss of growth control and membrane synthesis dysregulation) and AD (through cholinergic system failure). The differential expression—cancer versus AD—depends on additional factors determining which failure mode dominates, but the fundamental metabolic vulnerability derives from this energetic constraint.



Alpha-Ketoglutarate Dehydrogenase Complex: The Critical Metabolic Junction



KGDHC Function, Regulation, and Vulnerability

The alpha-ketoglutarate dehydrogenase complex catalyzes irreversible oxidative decarboxylation of alpha-ketoglutarate to succinyl-CoA, generating NADH and CO₂ 14. This multi-enzyme complex requires five cofactors: thiamine pyrophosphate, lipoic acid, coenzyme A, NAD⁺, and Mg²⁺. KGDHC represents the rate-limiting step of the TCA cycle under many physiological conditions and exhibits complex regulation by substrate availability, product inhibition (succinyl-CoA, NADH), calcium activation, and post-translational modifications.



KGDHC shows particular vulnerability to oxidative damage due to reactive lipoic acid residues susceptible to reactive oxygen species 14. This vulnerability creates a vicious cycle: oxidative stress damages KGDHC, reducing its activity; reduced KGDHC activity impairs NADH production and ATP synthesis; impaired ATP synthesis compromises antioxidant defenses; increased oxidative stress further damages KGDHC. Additionally, KGDHC demonstrates tissue-specific expression patterns and age-related decline, with brain tissue exhibiting particularly pronounced vulnerability.



KGDHC Deficiency in Alzheimer's Disease: The Cold Stress Foundation

AD brains consistently demonstrate 50-75% reduction in KGDHC activity across multiple brain regions including hippocampus, cortex, and cerebellum 14. This reduction correlates with disease severity and appears early in disease progression—KGDHC activity declines are detectable in mild cognitive impairment preceding overt dementia, suggesting causative rather than consequential involvement 15. Post-mortem studies confirm marked KGDHC reduction in AD brains, with the degree of reduction correlating with neurofibrillary tangle density and cognitive impairment severity.



KGDHC deficiency creates the "cold stress" state through alpha-ketoglutarate accumulation. When KGDHC activity falls 50-75% below normal, the TCA cycle cannot efficiently metabolize alpha-ketoglutarate, leading to its accumulation. This accumulation disrupts multiple downstream processes: impaired ATP synthesis from reduced NADH production, altered glutamate/GABA balance as accumulated alpha-ketoglutarate transaminates to glutamate, and potentially altered alpha-ketoglutarate-dependent dioxygenase function affecting epigenetic regulation and hypoxia responses 14.



The GABA shunt represents the alternative pathway that could potentially compensate for KGDHC deficiency by channeling glutamate through GABA to succinate, bypassing the alpha-ketoglutarate dehydrogenase step. However, this compensatory mechanism requires functional GABA systems—specifically, intact glutamate decarboxylase, GABA transaminase, and succinate semialdehyde dehydrogenase, coordinated by GABA receptor signaling. In individuals with dual-GABA system deficiency, this compensatory pathway fails, leaving alpha-ketoglutarate accumulation unopposed. This explains why KGDHC deficiency proves particularly devastating in AD: the backup system cannot engage 27.



Alpha-Ketoglutarate Dysregulation in Cancer: Context-Dependent Pathology

Cancer cells demonstrate context-dependent alpha-ketoglutarate dysregulation that may involve either accumulation or depletion depending on specific genetic alterations and tissue context. Cancers with isocitrate dehydrogenase (IDH) mutations—particularly IDH1/2 mutations in gliomas and acute myeloid leukemia—show altered alpha-ketoglutarate metabolism through neomorphic enzyme activity producing 2-hydroxyglutarate from alpha-ketoglutarate 30. This depletes alpha-ketoglutarate while producing an oncometabolite that competitively inhibits alpha-ketoglutarate-dependent dioxygenases.



Conversely, cancers without IDH mutations frequently show alpha-ketoglutarate accumulation similar to AD, particularly when mitochondrial function becomes impaired. The Warburg effect—aerobic glycolysis in cancer—often accompanies reduced TCA cycle flux and potentially reduced KGDHC activity, leading to alpha-ketoglutarate accumulation. This accumulation may actually support certain aspects of oncogenesis by providing substrate for biosynthetic reactions using alpha-ketoglutarate as nitrogen acceptor, facilitating rapid growth.



Alpha-ketoglutarate-dependent dioxygenases play critical roles in cancer biology: prolyl hydroxylases regulating HIF-mediated hypoxia responses; TET enzymes catalyzing DNA demethylation affecting tumor suppressor expression; JmjC-domain histone demethylases modifying chromatin structure. Alpha-ketoglutarate availability directly influences these regulatory mechanisms—either accumulation or depletion disrupts normal regulation, contributing to oncogenic transformation through epigenetic dysregulation and altered hypoxia adaptation 29.



The key insight is that alpha-ketoglutarate dysregulation—regardless of direction—proves oncogenic when it disrupts normal regulatory balance. In the context of dual-GABA deficiency, the loss of metabolic flexibility and regulatory capacity means cells cannot appropriately adjust alpha-ketoglutarate levels in response to changing demands, creating vulnerability to oncogenic transformation.



Cancer: Failed Outward Discharge Manifesting as Proliferation



The Dual-GABA Deficiency Phenotype: Creating Metabolic Permissiveness



We hypothesize that individuals with deficient function in both ionotropic GABA-A and metabotropic GABA-B systems constitute a metabolic phenotype characterized by three interconnected vulnerabilities: (1) inability to regulate alpha-ketoglutarate accumulation through impaired GABA shunt function ("cold stress"), (2) disrupted circadian metabolic entrainment creating nocturnal vulnerability ("darkness stress"), and (3) impaired choline synthesis via SAM-dependent pathways due to energetic equivalence between dual-GABA and choline synthesis systems.



This phenotype creates metabolic permissiveness for oncogenesis through multiple synergistic mechanisms. Cold stress—alpha-ketoglutarate accumulation—disrupts mitochondrial function, reducing ATP synthesis while increasing reactive oxygen species production, thereby generating genomic instability. Darkness stress—circadian dysregulation—disrupts temporal coordination of DNA repair, cell cycle checkpoints, and immune surveillance, creating windows of vulnerability when normal protective mechanisms fail 31. Impaired choline synthesis disrupts membrane homeostasis and SAM-dependent methylation, contributing to epigenetic dysregulation characteristic of cancer.



Critically, this phenotype does not itself constitute cancer—it creates metabolic conditions permissive for oncogenesis when additional hits occur. The phenotype explains: why shift workers show elevated cancer risk (their circadian disruption exacerbates underlying darkness stress) 10,11; why some individuals develop cancer despite no obvious risk factors (underlying dual-GABA deficiency creates vulnerability); why cancer shows strong circadian rhythmicity in incidence and progression (darkness stress creates temporal vulnerability windows).



Epinephrine and Proliferative Signaling Without Opposition

In the dual-GABA-deficient state, epinephrine-mediated proliferative signaling proceeds without proper inhibitory control. Normal physiology involves oscillation between growth-promoting adrenergic signaling and growth-restraining GABAergic inhibition, creating balanced cell cycle control. GABAergic systems provide counterbalance to adrenergic proliferative signals through multiple mechanisms: direct inhibition of growth signaling cascades, metabolic regulation limiting substrate availability for biosynthesis, and circadian entrainment coordinating growth with appropriate temporal windows 34.



Loss of dual-GABA regulatory capacity eliminates this counterbalance, allowing continuous proliferative signal flow. Epinephrine signaling promotes cellular proliferation through: cyclic AMP-mediated transcription factor activation (CREB, AP-1), glycolytic enzyme upregulation providing metabolic substrates, growth factor receptor sensitization, and anti-apoptotic signaling. Without GABAergic opposition, these pathways remain constitutively active rather than oscillating appropriately.



The concept of "failed outward discharge" refers to the inability to externalize stress responses through appropriate behavioral or physiological actions. Normally, stress activates fight-or-flight responses channeling energy outward toward environmental challenges. In dual-GABA deficiency, this externalization fails—the stress response activates but cannot properly discharge, redirecting energy inward toward cellular processes. In cancer, this manifests as redirected proliferation: energy that should discharge outward instead drives internal cellular growth.



This framework explains several cancer characteristics: why stress associates with cancer risk (chronic stress without proper discharge), why cancer cells show "addiction" to growth signals (lost inhibitory control), why cancer demonstrates autonomous growth (internal redirection of stress responses). The epinephrine-mediated proliferation represents misdirected stress response energy flowing inward when outward discharge fails.



Circadian Vulnerability and Oncogenesis: Darkness Stress as Temporal Risk

Cancer incidence shows strong circadian associations validated across multiple lines of evidence. Shift workers, particularly those working rotating night shifts, demonstrate 40-50% elevated breast cancer risk and increased colorectal cancer risk 10,11. Circadian gene polymorphisms (CLOCK, BMAL1, PER genes) associate with cancer susceptibility across multiple cancer types. Tumor growth rates exhibit circadian rhythms with faster growth during specific circadian phases. These observations support fundamental circadian disruption in cancer etiology rather than mere correlative association 31,32.



The metabotropic GABA-B system plays a critical role in circadian metabolic entrainment, coordinating cellular metabolism with environmental light-dark cycles. Deficiency in metabotropic GABA function creates "darkness stress"—nocturnal charge dysregulation when compensatory mechanisms that function during daylight fail during dark periods. This creates particular vulnerability during nighttime hours when: DNA repair processes normally peak but fail to properly activate, cell cycle checkpoints normally arrest proliferation but lose effectiveness, immune surveillance normally clears aberrant cells but becomes impaired, and melatonin normally exerts anti-proliferative effects but cannot compensate for underlying GABA deficiency 33.



The accumulation of nocturnal insults over years—unrepaired DNA damage, escaped cell cycle checkpoint failures, immune surveillance gaps—creates conditions favoring oncogenic transformation. Each night represents a vulnerability window; over decades, the cumulative damage burden increases cancer risk substantially. This explains why relatively modest circadian disruption (shift work) meaningfully increases cancer risk: it exacerbates underlying darkness stress, expanding temporal vulnerability windows and accelerating oncogenic transformation.



Melatonin represents the primary hormonal signal of darkness, exhibiting potent anti-proliferative and antioxidant properties. However, melatonin cannot fully compensate for dual-GABA deficiency—its effects depend partly on functional GABA systems for full efficacy. This explains why melatonin supplementation shows promise in cancer prevention and treatment but yields inconsistent results: it partially addresses darkness stress but cannot restore underlying dual-GABA function 16,33.



Alzheimer's Disease: Failed Outward Discharge Manifesting as Autoimmune-Like Neurodegeneration

The Same Metabolic Foundation, Opposite Clinical Expression

Alzheimer's disease emerges from an identical metabolic foundation as cancer—dual-GABA system deficiency creating cold stress and darkness stress—but manifests as inward-directed neurodegeneration rather than proliferation. The differential expression depends on which stress response pathways activate: cancer emerges through epinephrine-mediated proliferative pathways while AD emerges through vasopressin-mediated inflammatory pathways. This likely reflects genetic polymorphisms in stress response systems, differential tissue vulnerabilities, and individual stress exposure histories determining which pathway dominates.



The KGDHC deficiency in AD brains—50-75% activity reduction across multiple regions—represents cold stress identical in mechanism to cancer's alpha-ketoglutarate dysregulation 14. The severe circadian disruption in AD—sundowning syndrome, sleep-wake cycle reversal, reduced melatonin production—reflects the same darkness stress underlying cancer's circadian vulnerability 16. The cholinergic system collapse in AD—ChAT reduction, acetylcholine deficiency, basal forebrain neuronal loss—reflects the same impaired choline synthesis capacity that creates altered choline metabolism in cancer 13.



These parallel metabolic foundations explain the inverse epidemiological relationship: both diseases require the same underlying metabolic vulnerability (dual-GABA deficiency), but once one pathway activates and dominates the phenotype, it precludes the other. Cancer's proliferative metabolism may actively protect against neurodegeneration by maintaining growth factor signaling preventing inflammatory cascades. Conversely, AD's inflammatory state may suppress oncogenesis through enhanced immune surveillance and growth suppression signals. The two diseases represent mutually exclusive failure modes of shared metabolic vulnerability.



Vasopressin and Redirected Inflammatory Aggression

While cancer emerges through epinephrine-mediated proliferation, AD emerges through vasopressin-mediated stress responses that cannot discharge externally and redirect inward as inflammatory neurodegeneration. Vasopressin systems normally facilitate aggressive responses to external threats—territorial defense, stress coping, social challenge response. In dual-GABA-deficient individuals, these responses activate but cannot properly discharge outward, instead redirecting inward against neural tissue.



This "failed outward discharge" manifests as autoimmune-like neurodegeneration—not classical autoimmunity with anti-neuronal antibodies, but rather stress-induced inflammatory cascades proceeding without counterbalancing GABAergic inhibition. Microglial activation, normally a protective response clearing damaged cells and pathogens, becomes chronic and excessive without GABAergic restraint. Astrocyte reactivity, normally supporting neuronal function during stress, transforms into neurotoxic phenotypes releasing pro-inflammatory mediators. Inflammatory cytokine production (IL-1β, TNF-α, IL-6), normally acute and self-limiting, becomes sustained and damaging 35.



The loss of noradrenergic locus coeruleus neurons early in AD progression compounds this inflammatory dysregulation. Noradrenergic signaling normally provides anti-inflammatory control through β2-adrenergic receptors on microglia, restraining inflammatory activation. Locus coeruleus degeneration eliminates this control, permitting inflammatory escalation creating feed-forward neurodegeneration: initial neuronal stress activates microglia, microglial activation damages more neurons, increased neuronal damage further activates microglia 36.



The vasopressin-mediated pathway explains several AD characteristics: why stress accelerates AD progression (chronic stress activates vasopressin systems), why AD demonstrates inflammatory pathology (redirected inflammatory stress responses), why AD shows regional selectivity (stress response system connectivity determines vulnerable regions). The neurodegeneration represents misdirected stress response—inflammatory energy that should discharge outward instead attacks internal neural tissue when outward discharge fails.



Cholinergic System Collapse: Metabolic Insufficiency Becoming Structural Failure

The profound cholinergic system degeneration in AD—marked ChAT reduction, acetylcholine deficiency, basal forebrain neuronal loss—connects directly to the choline-GABA-SAM metabolic framework. Dual-GABA deficiency energetically equals impaired choline synthesis capacity through the energetic equivalence between these systems. As disease progresses, this metabolic limitation becomes structural: cholinergic neurons cannot maintain themselves and degenerate.



Basal forebrain cholinergic neurons projecting throughout cortex exhibit particular vulnerability reflecting their exceptional metabolic demands. These neurons require: continuous choline supply for acetylcholine synthesis at high rates, robust SAM availability for membrane maintenance and gene expression, intact mitochondrial function for ATP production supporting synaptic transmission, and functional antioxidant defenses protecting against oxidative stress from high metabolic activity 12. In the metabolically compromised state of dual-GABA deficiency with cold stress and darkness stress, these neurons gradually fail—their demands exceed available metabolic capacity.



The preferential vulnerability of cholinergic neurons explains why cholinergic deficiency appears early in AD progression, often preceding overt cognitive decline. These neurons serve as metabolic "canaries in the coal mine"—their high demands mean they fail first when metabolic insufficiency develops. This also explains why acetylcholinesterase inhibitors, while providing symptomatic benefit, cannot halt disease progression: they increase acetylcholine availability but cannot restore underlying metabolic capacity 12.



The cholinergic system collapse represents the intersection of all three metabolic stresses: cold stress (KGDHC deficiency) limits ATP availability for neurotransmitter synthesis and release; darkness stress (circadian disruption) desynchronizes cholinergic neuron activity from appropriate temporal patterns; impaired choline synthesis limits substrate availability for acetylcholine production. The synergistic effect of these three stresses on neurons with maximal metabolic demands explains the dramatic cholinergic deficit characteristic of AD.



Hypothesis Testing



Biomarker Validation

We predict distinct metabolic signatures for the two disease states. Cancer patients should exhibit a "Growth Profile" characterized by elevated choline metabolites (phosphocholine) but reduced GABAergic activity. Conversely, Alzheimer’s patients should exhibit a "Degeneration Profile" characterized by depleted choline levels and reduced GABAergic activity. We specifically predict that the ratio of alpha-ketoglutarate to succinate during the nocturnal circadian peak will differ significantly between the two groups, reflecting the divergent metabolic outcomes of the shared GABAergic failure.



Genetic Associations

We predict opposing genetic risk factors regarding choline synthesis. Individuals with high-activity variants of the *PEMT* gene (enhanced choline synthesis) should show increased risk for Cancer but protection against Alzheimer’s. Conversely, individuals with low-activity *PEMT* variants should show increased risk for Alzheimer’s but protection against Cancer. However, we predict that loss-of-function variants in GABA receptor genes (*GABRA*, *GABRB*) will be a shared risk factor common to both diseases.



Clinical Interventions

Our framework predicts that metabolic interventions will have opposing effects. Supplementation with SAMe or Choline, which fuels methylation and membrane synthesis, should improve cognitive function in Alzheimer’s disease but may accelerate tumor growth in Cancer. In contrast, GABAergic agonists that restore inhibitory control should prove therapeutic for both conditions—suppressing proliferation in Cancer and dampening neuroinflammation in Alzheimer’s. Finally, we predict that circadian-based therapies (chronotherapy) targeting the "Darkness Stress" window will be essential for preventing both pathologies.



Implications



Unified Prevention Strategies

If validated, this framework implies that cancer and AD prevention strategies should overlap substantially, focusing on upstream metabolic resilience rather than disease-specific downstream targets. Key preventative measures would include: (1) Circadian hygiene: strict sleep-wake regularity, avoidance of light at night, and potentially timed melatonin supplementation to prevent "darkness stress." (2) Metabolic support: dietary strategies minimizing insulin resistance and potentially supporting GABAergic function. (3) Stress management: reducing chronic stress burden to prevent the "failed outward discharge" that drives both proliferative and inflammatory pathologies.



Chronotherapy: Timing as Treatment

The "darkness stress" concept emphasizes that *when* we treat may be as important as *what* we treat. Interventions targeting GABAergic or metabolic systems may require specific circadian timing—likely evening or night administration—to restore the lost nocturnal regulatory capacity. Administering metabolic support during the vulnerability window (darkness) could prevent the charge dysregulation initiating both pathologies.



Redefining Disease Classifications

Recognizing cancer and AD as mirror pathologies challenges current disease taxonomies separating oncology and neurology. It suggests a "metabolic spectrum" classification where diseases are defined by their underlying energetic failure mode (e.g., "Dual-GABA Deficient Proliferative Type" vs. "Dual-GABA Deficient Degenerative Type") rather than organ system alone. This could accelerate therapeutic discovery by allowing insights from cancer metabolism to inform AD treatment and vice versa.



Conclusion



We propose that Alzheimer's disease and cancer represent mirror pathologies arising from a shared metabolic origin: dual GABAergic system deficiency creating simultaneous cold stress (KGDHC dysfunction) and darkness stress (circadian dysregulation). This framework explains the robust inverse epidemiological relationship between these diseases not as coincidence, but as mutual exclusivity rooted in energetic equivalence. When the GABAergic "brakes" fail and circadian "grounding" is lost, the system must either discharge energy outwardly through uncontrolled proliferation (Cancer) or redirect it inwardly through inflammatory degeneration (Alzheimer's). By targeting the upstream metabolic and circadian failures rather than just the downstream symptoms, we may unlock unified therapeutic strategies capable of preventing both of these devastating age-related pathologies.



---



Ethics statement

This manuscript is a hypothesis-based work and does not include any experiments involving human participants, animals, or identifiable human data. Hence, ethical approval and informed consent were not applicable.



Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.



Conflict of interest

The author declares no competing interests.



References



1. Driver JA, Beiser A, Au R, et al. Inverse association between cancer and Alzheimer's disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442.

2. Ganguli M. Cancer and dementia: it's complicated. Alzheimer Dis Assoc Disord. 2015;29(2):177-182.

3. Zheng G, Xu M, Dong Z, Abdelrahman Z, Wang X. Meta-analysis reveals an inverse relationship between Alzheimer's disease and cancer. Behav Brain Res. 2025 Feb 26;478:115327. 

4. Roe CM, Fitzpatrick AL, Xiong C, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74(2):106-112.

5. Glunde K, Bhujwalla ZM, Ronen SM. Choline metabolism in malignant transformation. Nat Rev Cancer. 2011;11(12):835-848.

6. Iorio E, Mezzanzanica D, Alberti P, et al. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005;65(20):9369-9376.

7. Podo F, Canevari S, Canese R, et al. MR evaluation of response to targeted treatment in cancer cells. NMR Biomed. 2011;24(6):648-672.

8. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001;93(20):1557-1562.

9. Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire fighting. Lancet Oncol. 2007;8(12):1065-1066.

10. Terry AV Jr, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003;306(3):821-827.

11. Chen ZR, Huang JB, Yang SL, Hong FF. Role of cholinergic signaling in Alzheimer's disease. Molecules. 2022;27(6):1816.

12. Gibson GE, Park LC, Sheu KF, et al. The alpha-ketoglutarate dehydrogenase complex in neurodegeneration. Neurochem Int. 2000;36(2):97-112.

13. Sorbi S, Bird ED, Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol. 1983;13(1):72-78.

14. Cardinali DP, Furio AM, Brusco LI. Clinical aspects of melatonin intervention in Alzheimer's disease progression. Curr Neuropharmacol. 2010;8(3):218-227.

15. Ye C, Sutter BM, Wang Y, et al. A metabolic function for phospholipid and histone methylation. Mol Cell. 2017;66(2):180-193.2000;41(8):1310-1316.

16. Ivanov A, Nash-Barboza S, Hinkis S, Caudill MA. Genetic variants in phosphatidylethanolamine N-methyltransferase and methylenetetrahydrofolate dehydrogenase influence biomarkers of choline metabolism when folate intake is restricted. J Am Diet Assoc. 2009;109(2):313-318.

17. Obeid R, Herrmann W. Homocysteine and lipids: S-Adenosyl methionine as a key intermediate. FEBS Lett. 2009;583(8):1215-1225.

18. Fischer LM, daCosta KA, Kwock L, et al. Sex and menopausal status influence human dietary requirements for the nutrient choline. Am J Clin Nutr. 2007;85(5):1275-1285.

19. Ramírez de Molina A, Rodríguez-González A, Gutiérrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun. 2002;296(3):580-583.

20. Poly C, Massaro JM, Seshadri S, et al. The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. Am J Clin Nutr. 2011;94(6):1584-1591.

21. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Pharmacol Rev. 2008;60(3):243-260.

22. Bettler B, Kaupmann K, Mosbacher J, Gassmann M. Molecular structure and physiological functions of GABA(B) receptors. Physiol Rev. 2004;84(3):835-867.

23. Shelp BJ, Bown AW, McLean MD. Metabolism and functions of gamma aminobutyric acid. Trends Plant Sci. 1999;4(11):446-452.

24. Wan S, Niu Y, Zhang X, et al. Disruption of cyanobacterial γ-aminobutyric acid shunt pathway increases production of glycogen and polyhydroxybutyrate. Sci Rep. 2019;9:8171.

25. Carey BW, Finley LW, Cross JR, et al. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413-416.

26. Sulli G, Lam MTY, Panda S. Interplay between circadian clock and cancer: new frontiers for cancer treatment. Trends Cancer. 2019;5(8):475-494.

27. Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell. 2016;30(6):909-924.

28. Hill SM, Belancio VP, Dauchy RT, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer. 2015;22(3):R183-R204.

29. Joëls M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci. 2009;10(6):459-466.

30. Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388-405.

31. Mather M, Harley CW. The locus coeruleus: essential for maintaining cognitive function and the aging brain. Trends Cogn Sci. 2016;20(3):214-226.





